Overview

Study of BMS-986158 in Subjects With Select Advanced Cancers

Status:
Active, not recruiting
Trial end date:
2021-08-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Nivolumab